OHR PHARM
Seite 2 von 3 Neuester Beitrag: 04.02.19 14:44 | ||||
Eröffnet am: | 05.02.14 17:27 | von: macos | Anzahl Beiträge: | 56 |
Neuester Beitrag: | 04.02.19 14:44 | von: daniellalos | Leser gesamt: | 38.157 |
Forum: | Börse | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 > |
Es scheint sich doch noch was zu tun bei OHR, auch wenn es sehr still geworden ist . . .
http://www.nasdaq.com/de/symbol/ohrp/real-time
https://seekingalpha.com/article/...te-best-risk-reward-wet-amd-space
...
We are very disappointed with the outcome of the MAKO study, commented Dr. Jason Slakter, chief executive officer of Ohr. We are grateful to the patients and physicians who participated in the clinical trial. Based on these results, we intend to evaluate strategic alternatives to maximize shareholder value.
...
vorbörslich fällt die Aktie an der nasdaq schon über 40% und auch in Stuttgart geht's runter.
http://www.nasdaq.com/de/symbol/ohrp/premarket
https://www.boerse-stuttgart.de/de/boersenportal/...NOTATION=96303597
wieso der massive Absturz der Aktie? oO ich kaufe mich morgen mal ordentlich hier ein :D schadet nicht xD
https://seekingalpha.com/news/3321351-ohr-pharmas-mako-study-fails
"Based on these results, we intend to evaluate strategic alternatives to maximize shareholder value.”"
was ist denn genau passiert?
Nachrichtenquelle : Business Wire (engl.)
23.02.2018, 00:43 | 275 Leser
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OHR Pharmaceutical, Inc. (“OHR” or the “Company”) (NASDAQ:OHRP).
On January 4, 2018, OHR issued a press release announcing negative results from its study evaluating the safety and efficacy of Squalamine, the Company’s leading therapeutic candidate for improving vision outcomes in patients suffering from ophthalmic diseases. Specifically, patients receiving the Squalamine combination therapy failed to show vision improvement over candidates receiving only a Lucentis monotherapy.
On this news, OHR’s share price declined significantly, causing harm to investors.